MyoCardioCare Receives Two QTDP Grants
ROCHESTER, NY, November 22, 2010 -- MyoCardioCare, Inc., a medical device company which is commercializing innovative, life-saving, acute circulatory support systems for patients in cardiac arrest, announced today that it has been awarded two grants from the Qualifying Therapeutic Discover Project (QTDP) grant program totaling $244,000.
QTDP recipients were required to meet predefined standards in their research in order to receive funding. Applicants were required to demonstrate the potential to address unmet medical needs, produce new therapies, reduce the upward climb of costs or advance the goal of curing cancer within the next 30 years. Preference was given to companies that showed the greatest potential to create and sustain high-quality, high-paying jobs in the U.S. and advance the country's competitiveness in the fields of life, biological, and medical sciences.
“We believe that the award of these grants is an acknowledgment of the importance of MyoCardioCare’s technology in addressing the unmet medical needs of patients in cardiac arrest” stated Melissa Mahler, Executive Vice President of MyoCardioCare.
John Lanzafame, President of MyoCardioCare, commented, “The QTDP grants will be instrumental in helping us complete the commercialization of our technology, moving us a major step closer to beginning first in man studies and clinical trials for the MCC3000.”
The QTDP is provided under Section 48D of the Internal Revenue Code, enacted as part of the Patient Protection and Affordable Health Care Act of 2010.
About the MCC3000 and MyoCardioCare, Inc.
MyoCardioCare is commercializing an innovative heart pump that has the potential to save millions of lives. The device, the MCC3000, is the first in a family of products based upon Direct Mechanical Ventricular Actuation (DMVA) technology. It consists of a flexible polymer "cup" that can be installed around the heart in under five minutes. Incorporating a pneumatically activated liner, the MCC3000 operates by compressing and expanding bi-directionally, providing the energy that allows the heart to restore the blood flow to normal, life-sustaining levels. A previous version of the technology had helped save human lives in emergency-use situations by providing circulatory support to patients for between 2 and 83 days.
The MCC3000 energizes the best blood pump known to man: the human heart. Since it does not contact circulating blood, as do virtually all existing cardiac assist devices, the MCC3000 has the potential to reduce or avoid complications which plague existing devices, including clotting, stroke, bleeding, and infection. Additionally, the healing environment created by the MCC3000 has the potential to rehabilitate many sick hearts, allowing the device to be removed and the heart to function properly again without assistance.
The first generation of the MCC3000 to be introduced will enable the trained physician to quickly restore cardiac function and blood flow to resuscitate cardiac arrest patients. This procedure could be performed in life-saving emergency situations in hospitals around the world.
For more information about MyoCardioCare, Inc. please visit our website at www.myocardiocare.com.
Contact:
John Lanzafame, President
Phone: (877) 778-2696
Fax: (877) 778-2685
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
_______________________________________________________________________________________________________________
MyoCardioCare, Inc. Appoints Renowned Surgeon Dr. Gus Vlahakes to Scientific Advisory Board
ROCHESTER, NY, November 17, 2010 -- MyoCardioCare, Inc., a medical device company which is commercializing innovative, life-saving, acute circulatory support systems for patients in cardiac arrest, announces the appointment of Dr. Gus J. Vlahakes to its Scientific Advisory Board. Dr. Vlahakes will be providing clinical guidance in the development of MyoCardioCare’s next-generation technologies.
He has been on the Staff at Massachusetts General Hospital for the last 25 years, and has been involved with mechanical circulatory support since 1987. He has been principle investigator on numerous clinical trials of circulatory support devices during his tenure on the staff at Massachusetts General Hospital.
John F. Lanzafame, President of MyoCardioCare, commented, “We are excited to welcome Dr. Vlahakes to MyoCardioCare’s Scientific Advisory Board. His leadership in the field of cardiac surgery and his extensive experience with circulatory support devices will provide great insight as we commercialize the MCC3000."
Dr. Vlahakes is an engineering graduate of MIT and received his MD degree from Harvard Medical School. He received his general surgery and cardiothoracic surgical training at Massachusetts General Hospital and Boston Children's Hospital. He completed a three-year cardiac physiology fellowship at the Cardiovascular Research Institute at the University of California, San Francisco.
Dr. Vlahakes is joined on the MyoCardioCare’s Scientific Advisory Board by Dr. Brian Gibler who was recently appointed President & CEO of the University of Cincinnati Hospital and Senior Vice President of UC Health.
About the MCC3000 and MyoCardioCare, Inc.
MyoCardioCare is commercializing an innovative heart pump that has the potential to save millions of lives. The device, the MCC3000, is the first in a family of products based upon Direct Mechanical Ventricular Actuation (DMVA) technology. It consists of a flexible polymer "cup" that can be installed around the heart in under five minutes. Incorporating a pneumatically activated liner, the MCC3000 operates by compressing and expanding bi-directionally, providing the energy that allows the heart to restore the blood flow to normal, life-sustaining levels. A previous version of the technology had helped save human lives in emergency-use situations by providing circulatory support to patients for between 2 and 83 days.
The MCC3000 energizes the best blood pump known to man: the human heart. Since it does not contact circulating blood, as do virtually all existing cardiac assist devices, the MCC3000 has the potential to reduce or avoid complications which plague existing devices, including clotting, stroke, bleeding, and infection. Additionally, the healing environment created by the MCC3000 has the potential to rehabilitate many sick hearts, allowing the device to be removed and the heart to function properly again without assistance.
The first generation of the MCC3000 to be introduced will enable the trained physician to quickly restore cardiac function and blood flow to resuscitate cardiac arrest patients. This procedure could be performed in life-saving emergency situations in hospitals around the world.
For more information about MyoCardioCare, Inc. please visit our website at www.myocardiocare.com.
Contact:
John Lanzafame, President
Phone: (877) 778-2696
Fax: (877) 778-2685
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
___________________________________________________________________________________________________________
MyoCardioCare, Inc. Appoints Internationally Recognized Dr. Brian Gibler to Scientific Advisory Board
(Rochester, NY) September 23, 2010 -- MyoCardioCare, Inc., a medical device company which is commercializing innovative, life-saving, acute circulatory support systems for patients in cardiac arrest, announces the appointment of Dr. Brian Gibler to its Scientific Advisory Board. Dr. Gibler will be providing clinical guidance in the development of MyoCardioCare’s next-generation technologies. Dr. Gibler currently serves as the Richard C. Levy Professor of Emergency Medicine and Chairman of the Department of Emergency at the University of Cincinnati College of Medicine. He is also the Director for the Center of Emergency Care of the University of Cincinnati Hospital in Cincinnati, Ohio.
Dr. Gibler is an editor and referee for numerous Emergency Medicine and Cardiology journals and has published numerous peer-reviewed articles on the early diagnosis and treatment of Acute Coronary Syndrome in the Emergency Medicine and Cardiology literature. He is internationally known for his efforts in creating a multicenter trials group, the Emergency Medicine Cardiac Research Group (EMCREG)-International. He was also a member of the International GUSTO Trials Steering Committee and served as a member of the National Heart Attack Alert Program Working Group.
Frank W. Terrizzi, Chairman and CEO of MyoCardioCare, commented, "We are extremely pleased to have Brian Gibler, a well recognized and respected leader in the field of Emergency Medicine, join MyoCardioCare. We look forward to Dr. Gibler's contributions to our efforts to serve patients suffering from cardiac arrest."
John Lanzafame, President added, "I'm delighted to welcome Dr. Gibler to the MyoCardioCare team and look forward to working with him."
In 2008, the Board of Trustees of the Society of Chest Pain Centers bestowed upon Dr. Gibler the Raymond D Bahr Award of Excellence at the 11th Congress of Chest Pain Centers in Orlando, Florida. This award is given to individuals who demonstrate extraordinary vision, leadership, and excellence in advancing healthcare. In 1999, Dr. Gibler received the Hospital Hero Award from the Cincinnati Business Courier for his work on Chest Pain Centers. He has been voted to the Cincinnati Business Courier Best Doctor list from 2007-2010. In 1995, Dr. Gibler was awarded the Outstanding Contribution to Research Award from the American College of Emergency Physicians, and Best Original Research Paper at the 3rd International Conference on Emergency Medicine in Toronto, Canada in 1990.
Dr. Gibler's educational accomplishments include an M.D. from the Vanderbilt University Medical School, and a Sc.B. in Biology from Brown University where he graduated magna cum laude. Dr. Gibler is a graduate of the University of Cincinnati Emergency Medicine Residency Training Program.
About the MCC3000 and MyoCardioCare, Inc.
MyoCardioCare is commercializing an innovative heart pump that has the potential to save millions of lives. The device, the MCC3000, is the first in a family of products based upon Direct Mechanical Ventricular Actuation (DMVA) technology. It consists of a flexible polymer "cup" that can be installed around the heart in under five minutes. Incorporating a pneumatically activated liner, the MCC3000 operates by compressing and expanding bi-directionally, providing the energy that allows the heart to restore the blood flow to normal, life-sustaining levels. A previous version of the technology had helped save human lives in emergency-use situations by providing circulatory support to patients for between 2 and 83 days.
The MCC3000 energizes the best blood pump known to man: the human heart. Since it does not contact circulating blood, as do virtually all existing cardiac assist devices, the MCC3000 has the potential to reduce or avoid complications which plague existing devices, including clotting, stroke, bleeding, and infection. Additionally, the healing environment created by the MCC3000 has the potential to rehabilitate many sick hearts, allowing the device to be removed and the heart to function properly again without assistance.
The first generation of the MCC3000 to be introduced will enable the trained physician to quickly restore cardiac function and blood flow to resuscitate cardiac arrest patients. This procedure could be performed in life-saving emergency situations in hospitals around the world.
For more information about MyoCardioCare, Inc. please visit our website at www.myocardiocare.com.
Contact:
John Lanzafame, President
Phone: (877) 778-2696
Fax: (877) 778-2685
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
___________________________________________________________________________________________________________
MyoCardioCare purchases innovative heart pump technology
(Rochester, NY) September 8, 2009 -- MyoCardioCare, Inc. (MCC), a privately owned company, recently purchased an innovative heart pump technology from Biophan Technologies, Inc. The company plans to complete the final stages of the device’s development. As a condition of the sale, Biophan retained a 20 percent equity interest in MyoCardioCare.
“This device has unique capabilities that will fill an important unmet need in the acute resuscitation market,” said John Lanzafame, president. “We look forward to bringing this life-saving device to the market.”
The novel design of the device, the MCC3000, employs a single-use, pneumatically powered, flexible, polymer cup that rhythmically compresses and expands the heart, restoring and maintaining circulation. This technology is able to support the patient, and provide a bridge to surgery, transplant or other forms of treatment. It is designed to have lower risk of complications than other circulatory support technologies, which have high incidences of blood clots, infections and other issues.
Originally pioneered in the 1990s, early prototypes of this technology were used on several patients at Duke University, and provided full circulatory support for 2 to 83 days. Innovations made since then have overcome some limitations that prevented its successful commercialization.
The device can be installed and activated in less than five minutes, providing a new option for patients in cardiac arrest. No other circulatory support technology can be applied this quickly.
“We believe that this device will provide a much needed option for cardiac arrest patients, who are poorly served by existing circulatory support devices,” Lanzafame said. “In addition to the speed of installation and its lower risk design, it is the only technology that provides full systolic and diastolic support to both ventricles.”
In addition to acute resuscitation, the device has several potential future applications, including patient support during emergency transport and providing a new vehicle for therapeutic and drug delivery technologies.
